184 related articles for article (PubMed ID: 14739781)
1. Family feud in chemosensitvity: p73 and mutant p53.
Irwin MS
Cell Cycle; 2004 Mar; 3(3):319-23. PubMed ID: 14739781
[TBL] [Abstract][Full Text] [Related]
2. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
3. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
[TBL] [Abstract][Full Text] [Related]
4. From p63 to p53 across p73.
Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G
FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031
[TBL] [Abstract][Full Text] [Related]
5. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
Vilgelm A; El-Rifai W; Zaika A
Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
[TBL] [Abstract][Full Text] [Related]
9. The p53 gene family.
Kaelin WG
Oncogene; 1999 Dec; 18(53):7701-5. PubMed ID: 10618710
[TBL] [Abstract][Full Text] [Related]
10. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of p73 and p53 regulation and effector functions.
Fang L; Lee SW; Aaronson SA
J Cell Biol; 1999 Nov; 147(4):823-30. PubMed ID: 10562283
[TBL] [Abstract][Full Text] [Related]
12. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
13. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships.
Mantovani F; Zannini A; Rustighi A; Del Sal G
Biochim Biophys Acta; 2015 Oct; 1850(10):2048-60. PubMed ID: 25641576
[TBL] [Abstract][Full Text] [Related]
14. The p53 family: same response, different signals?
Chen X
Mol Med Today; 1999 Sep; 5(9):387-92. PubMed ID: 10462750
[TBL] [Abstract][Full Text] [Related]
15. Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells.
Chakraborty J; Banerjee S; Ray P; Hossain DMS; Bhattacharyya S; Adhikary A; Chattopadhyay S; Das T; Sa G
J Biol Chem; 2010 Oct; 285(43):33104-33112. PubMed ID: 20675383
[TBL] [Abstract][Full Text] [Related]
16. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
17. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Li Y; Prives C
Oncogene; 2007 Apr; 26(15):2220-5. PubMed ID: 17401431
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for ASPP2 recognition by the tumor suppressor p73.
Canning P; von Delft F; Bullock AN
J Mol Biol; 2012 Nov; 423(4):515-27. PubMed ID: 22917970
[TBL] [Abstract][Full Text] [Related]
19. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
20. Role of p73 in malignancy: tumor suppressor or oncogene?
Stiewe T; Pützer BM
Cell Death Differ; 2002 Mar; 9(3):237-45. PubMed ID: 11859406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
